Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial


Martin M., Holmes F. A. , Ejlertsen B., Delaloge S., Moy B. , Iwata H., ...Daha Fazla

LANCET ONCOLOGY, cilt.18, ss.1688-1700, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 18 Konu: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/s1470-2045(17)30717-9
  • Dergi Adı: LANCET ONCOLOGY
  • Sayfa Sayıları: ss.1688-1700

Özet

Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.